What is the fair value of Uniqure NV (NASDAQ-QURE) stock?

The current fair value estimate for Uniqure NV (NASDAQ-QURE) is $33.18. This implies an estimated downside of 17.3% versus the current market price.

Is Uniqure NV (NASDAQ-QURE) undervalued or overvalued?

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 17.3% versus the current market price.

What is the analyst price target for NASDAQ-QURE stock?

The available analyst price target for Uniqure NV (NASDAQ-QURE) is $64.77. The analyst target implies estimated upside of 61.5%.

How is the financial health of Uniqure NV?

The current financial health read for Uniqure NV (NASDAQ-QURE) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Uniqure NV's next earnings date?

The next earnings date currently listed for Uniqure NV (NASDAQ-QURE) is August 4, 2026.

Does Uniqure NV (NASDAQ-QURE) pay dividends?

Based on the current data, dividend yield is 0.0%.

What is the P/E ratio for Uniqure NV (NASDAQ-QURE)?

The current P/E ratio listed for Uniqure NV (NASDAQ-QURE) is -13.2x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Uniqure NV?

The current market capitalization listed for Uniqure NV is 2.73 B.

What is the enterprise value of Uniqure NV?

The current enterprise value listed for Uniqure NV is 2.686 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Uniqure NV?

The ticker symbol for Uniqure NV is NASDAQ-QURE, and the stock is listed on NASDAQ.

Where is Uniqure NV (NASDAQ-QURE) listed?

Uniqure NV (NASDAQ-QURE) is listed on NASDAQ.

What is the debt-to-total-capital ratio for Uniqure NV?

The current debt-to-total-capital ratio listed for Uniqure NV is 16.7%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Uniqure NV?

The free float listed for Uniqure NV is 89.6%. Free float helps investors understand how much of the share base is available for public trading.

Uniqure NV (QURE) Fair Value & Stock Analysis

Uniqure NV (QURE)

uniQure N.V. is a Netherlands-based biotechnology company listed on NASDAQ under the ticker QURE. The company focuses on developing treatments for patients with rare and other serious diseases, with activities centered on gene therapy. Its marketed product is HEMGENIX, which is designed to help people with hemophilia B produce factor IX and may reduce bleeding risk. uniQure’s pipeline includes AMT-130, a lead gene therapy candidate being studied in phase I/II for Huntington’s disease, as well as AMT-260 for mesial temporal lobe epilepsy, AMT-162 for superoxide dismutase enzyme-associated amyotrophic lateral sclerosis, and AMT-191 for Fabry disease. The company also has a licensing arrangement with Apic Bio and a development and commercial supply agreement with CLS Bhering.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Upcoming Dividend Ex-Date	Dividend Payment Date	Upcoming Dividend	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Payout Ratio	Free Cash Flow / Net Income
NASDAQ-QURE	$33.18	-17.3% Downside	Fair	$64.77	61.5% Upside	Bargain	Fair	—	—	—	0.0%	August 4, 2026	-13.2x	18.5x	152.4x	2.73 B	2.686 B	16.7%	89.6%	0.4	—	82.6%

Send a message